Sheng X, et al. - Researchers assessed the effectiveness and safety of the combined therapies of sorafenib, gemcitabine, plus cisplatin in patients with metastatic collecting duct carcinoma (mCDC) 9n this prospective, multicenter, single-arm, open-label, phase 2 trial. In patients with mCDC, a similar outcome as that of the previously reported regimens was demonstrated by the combination of sorafenib and chemotherapy. Stil, this combination may be a suitable option for patients who have low Eastern Cooperative Oncology Group performance status or less metastatic sites.